The Trump administration intends to terminate a subsidy program that has been instrumental in keeping Medicare drug plan premiums affordable. This decision will affect approximately 25 million individuals enrolled in Medicare Part D plans, potentially leading to increased prescription coverage costs starting in 2027.

The program, which provides an estimated $3.6 billion in subsidies to insurance companies annually, is designed to mitigate premium hikes. Administration officials confirmed the program's cessation after 2026, asserting that the subsidies encouraged insurers to inflate rates, expecting government compensation. They maintain that these subsidies are no longer necessary and that other measures to control Part D costs remain active.

This development comes at a time when high drug costs are a significant concern, particularly for seniors on fixed incomes. Healthcare affordability is anticipated to be a prominent issue in upcoming elections. Beneficiaries will be informed of their 2027 premium rates in the fall.